CD274 and endometrial cancer: CR, complete response; DCR, disease control rate; DoR, duration of response; dMRR, mismatch repair-deficient; EC, endometrial cancer; FDA, Food and Drug Administration; ICI, immune checkpoint inhibitor; LAG-3, lymphocyte activation gene 3; mOS, median overall response; mPFS, median progression-free survival; ORR, overall response rate; OS, overall response; PARP, poly(ADP-ribose) polymerase; PD-L1, program-death death ligand-1; PFS, progression-free survival; pMMR, mismatch repair-proficient; RR, response rate; TKI, tyrosine kinase inhibitor